Esperion Therapeutics, Inc. (ESPR)

Market Cap	358.60M
Revenue (ttm)	295.45M
Net Income (ttm)	-86.77M
Shares Out	197.04M
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,961,957
Open	1.880
Previous Close	1.850
Day's Range	1.810 - 1.909
52-Week Range	1.580 - 3.940
Beta	1.01
Analysts	Buy
Price Target	7.25 (+298.35%)
Earnings Date	Mar 4, 2025

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products als...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 26, 2013
• Employees: 240
• Stock Exchange: NASDAQ
• Ticker Symbol: ESPR
• Website: https://www.esperion.com

Financial Performance

In 2023, Esperion Therapeutics's revenue was $116.33 million, an increase of 54.14% compared to the previous year's $75.48 million. Losses were -$209.25 million, -10.45% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $7.25, which is an increase of 298.35% from the latest price.

Price Target

$7.25

(298.35% upside)

Analyst Consensus: Buy